The burgeoning field of metabolic disease management is witnessing a exciting convergence of therapies. Semaglutide , a dual GIP/GLP-1 receptor agonist , alongside Retatrutide , a triple GIP/GLP-1/GCG receptor https://madesocials.com/story7196350/both-medications-and-nad-a-triple-threat-strategy-to-metabolic-condition